https://insights.citeline.com/generics-bulletin/ en All rights reserved The Generics Bulletin Podcast takes you inside the trends and decisions driving the global generics and biosimilars industry. Created for industry professionals, episodes published bi-monthly feature specialist reporters and expert voices unpacking regulatory shifts, pricing pressures, market access and competitive dynamics – alongside on-the-ground insights from key industry conferences. Visit us at https://insights.citeline.com/generics-bulletin to sign up for newsletters and stay ahead. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com. https://megaphone.imgix.net/podcasts/673cc74e-31a9-11f1-91fa-4bdd16de5f0f/image/31e2dd76a42ae3b74b1467ebbe68c9f0.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress https://insights.citeline.com/generics-bulletin/ episodic Norstella The Generics Bulletin Podcast takes you inside the trends and decisions driving the global generics and biosimilars industry. Created for industry professionals, episodes published bi-monthly feature specialist reporters and expert voices unpacking regulatory shifts, pricing pressures, market access and competitive dynamics – alongside on-the-ground insights from key industry conferences. Visit us at https://insights.citeline.com/generics-bulletin to sign up for newsletters and stay ahead. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com. The Generics Bulletin Podcast takes you inside the trends and decisions driving the global generics and biosimilars industry. Created for industry professionals, episodes published bi-monthly feature specialist reporters and expert voices unpacking regulatory shifts, pricing pressures, market access and competitive dynamics – alongside on-the-ground insights from key industry conferences. Visit us at https://insights.citeline.com/generics-bulletin to sign up for newsletters and stay ahead. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.

]]> Norstella webpubs@citeline.com On September 8, Sandoz revealed a slew of strategy updates and forecasts at a capital markets day at the London Stock Exchange. Generics Bulletin editor Dave Wallace was there, and discusses the key details with deputy editor Dean Rudge. Wed, 09 Sep 2026 19:59:00 -0000 full Norstella On September 8, Sandoz revealed a slew of strategy updates and forecasts at a capital markets day at the London Stock Exchange. Generics Bulletin editor Dave Wallace was there, and discusses the key details with deputy editor Dean Rudge. On September 8, Sandoz revealed a slew of strategy updates and forecasts at a capital markets day at the London Stock Exchange. Generics Bulletin editor Dave Wallace was there, and discusses the key details with deputy editor Dean Rudge.

]]> 833 no In the second episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė hears how patients with cystic fibrosis travelled to Bangladesh to collect generic version of Vertex’s highly inaccessible Trikafta. Urtė is joined by Wilna Lottering and her son Josh from South Africa, as well as Gayle Pledger, a cystic fibrosis campaigner. Wed, 02 Sep 2026 13:19:00 -0000 full Norstella In the second episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė hears how patients with cystic fibrosis travelled to Bangladesh to collect generic version of Vertex’s highly inaccessible Trikafta. Urtė is joined by Wilna Lottering and her son Josh from South Africa, as well as Gayle Pledger, a cystic fibrosis campaigner. In the second episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė hears how patients with cystic fibrosis travelled to Bangladesh to collect generic version of Vertex’s highly inaccessible Trikafta. Urtė is joined by Wilna Lottering and her son Josh from South Africa, as well as Gayle Pledger, a cystic fibrosis campaigner.

]]> 1354 no Wed, 19 Aug 2026 17:23:00 -0000 trailer Norstella 65 no Generics Bulletin’s senior reporter Urtė Fultinavičiūtė launches a new interview podcast series “Off-Patent, On Record.” In the inaugural episode, Urtė is joined by Dave Wallace, executive editor at Generics Bulletin, who has been covering the off-patent drug industry as a journalist and editor for 16 years. Tue, 04 Aug 2026 08:32:00 -0000 full Norstella Generics Bulletin’s senior reporter Urtė Fultinavičiūtė launches a new interview podcast series “Off-Patent, On Record.” In the inaugural episode, Urtė is joined by Dave Wallace, executive editor at Generics Bulletin, who has been covering the off-patent drug industry as a journalist and editor for 16 years. Generics Bulletin’s senior reporter Urtė Fultinavičiūtė launches a new interview podcast series “Off-Patent, On Record.” In the inaugural episode, Urtė is joined by Dave Wallace, executive editor at Generics Bulletin, who has been covering the off-patent drug industry as a journalist and editor for 16 years.

]]> 1456 no Oncology biosimilars have already helped expand access to established biologic treatments while supporting more sustainable healthcare spending. As the market moves towards increasingly complex therapies, however, identifying viable opportunities will require more than monitoring patent expiries. In this podcast, ICON experts Colin Farquharson and Martin Lachs, discuss how scientific innovation, evolving standards of care and changing market dynamics are influencing the next generation of oncology biosimilars. This podcast explores: How oncology biosimilars are moving from proof of concept towards broader adoption The potential opportunities and challenges associated with antibody-drug conjugates and bispecific antibodies Why patent expiry alone is not enough to determine the long-term viability of an asset The factors influencing physician confidence, patient acceptance and market uptake How real-world evidence can strengthen confidence in biosimilar safety and efficacy The analytical, CMC, regulatory and market-planning capabilities sponsors should develop early Wed, 22 Jul 2026 12:57:00 -0000 full Norstella Oncology biosimilars have already helped expand access to established biologic treatments while supporting more sustainable healthcare spending. As the market moves towards increasingly complex therapies, however, identifying viable opportunities will require more than monitoring patent expiries. In this podcast, ICON experts Colin Farquharson and Martin Lachs, discuss how scientific innovation, evolving standards of care and changing market dynamics are influencing the next generation of oncology biosimilars. This podcast explores: How oncology biosimilars are moving from proof of concept towards broader adoption The potential opportunities and challenges associated with antibody-drug conjugates and bispecific antibodies Why patent expiry alone is not enough to determine the long-term viability of an asset The factors influencing physician confidence, patient acceptance and market uptake How real-world evidence can strengthen confidence in biosimilar safety and efficacy The analytical, CMC, regulatory and market-planning capabilities sponsors should develop early

Oncology biosimilars have already helped expand access to established biologic treatments while supporting more sustainable healthcare spending. As the market moves towards increasingly complex therapies, however, identifying viable opportunities will require more than monitoring patent expiries. In this podcast, ICON experts Colin Farquharson and Martin Lachs, discuss how scientific innovation, evolving standards of care and changing market dynamics are influencing the next generation of oncology biosimilars. This podcast explores: How oncology biosimilars are moving from proof of concept towards broader adoption The potential opportunities and challenges associated with antibody-drug conjugates and bispecific antibodies Why patent expiry alone is not enough to determine the long-term viability of an asset The factors influencing physician confidence, patient acceptance and market uptake How real-world evidence can strengthen confidence in biosimilar safety and efficacy The analytical, CMC, regulatory and market-planning capabilities sponsors should develop early

]]> 1023 no Generics Bulletin's editorial team discusses the recent Medicines for Europe legal and annual conferences, attended by executive editor Dave Wallace, as well as the Medicines UK conference attended by reporter Anabel Costa-Ferreira. Mon, 20 Jul 2026 15:07:00 -0000 full Norstella Generics Bulletin's editorial team discusses the recent Medicines for Europe legal and annual conferences, attended by executive editor Dave Wallace, as well as the Medicines UK conference attended by reporter Anabel Costa-Ferreira. Generics Bulletin's editorial team discusses the recent Medicines for Europe legal and annual conferences, attended by executive editor Dave Wallace, as well as the Medicines UK conference attended by reporter Anabel Costa-Ferreira.

]]> 1341 no The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin Description: Generics Bulletin senior reporter Urtė Fultinavičiūtė talks to Tahir Amin, co-founder and CEO of I-MAK, about the current intellectual property system that curtails off-patent drug competition and global health equity. Thu, 18 Jun 2026 12:54:00 -0000 full Norstella The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin Description: Generics Bulletin senior reporter Urtė Fultinavičiūtė talks to Tahir Amin, co-founder and CEO of I-MAK, about the current intellectual property system that curtails off-patent drug competition and global health equity. The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin Description: Generics Bulletin senior reporter Urtė Fultinavičiūtė talks to Tahir Amin, co-founder and CEO of I-MAK, about the current intellectual property system that curtails off-patent drug competition and global health equity.

]]> 1722 no Generics Bulletin's editorial team discusses the recent Medicines for Europe biosimilars conference, attended by deputy editor Dean Rudge; while editor Dave Wallace talks about the latest big deals in biosimilars and what is behind them. Thu, 14 May 2026 12:01:00 -0000 full Norstella Generics Bulletin's editorial team discusses the recent Medicines for Europe biosimilars conference, attended by deputy editor Dean Rudge; while editor Dave Wallace talks about the latest big deals in biosimilars and what is behind them. Generics Bulletin's editorial team discusses the recent Medicines for Europe biosimilars conference, attended by deputy editor Dean Rudge; while editor Dave Wallace talks about the latest big deals in biosimilars and what is behind them.

]]> 1627 no